Pre-operative Epirubicin, Cisplatin, and Capecitabine in Patients With Newly Diagnosed Localised Oesophageal Adenocarcinoma
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Age > 18 years.
Histologically verified adenocarcinoma of the thoracic oesophagus or type 1, 2 and 3 tumours of the oesophagogastric junction (type 1 refers to lower oesophageal, type 2 refers to cardial and type 3 refers to subcardinal cancers).
AJCC Stage II-III (T2-3 N0-1 M0) (28), as assessed by spiral or multi-slice CT and endoscopic ultrasound, where primary surgery would be considered with curative intent.
No previous chemotherapy, radiotherapy or other investigational drug treatment for this indication.
WHO performance status 0,1 or 2.
Adequate bone marrow function with platelets > 100 x 109/l; WBC > 3 x 109/l; neutrophils > 1.5 x 109/l at the time of study entry.
Serum bilirubin < 35 mol/l.
Serum creatinine < 180 mol/l and measured creatinine clearance over 60ml/min.
No concurrent uncontrolled medical condition.
No previous malignant disease other than non-melanotic skin cancer or carcinoma in situ of the uterine cervix in the last 10 years.
Life expectancy > 3 months.
Adequate contraceptive precautions if relevant.
Informed written consent.
The presence of locally advanced or metastatic disease precluding curative surgical resection (T4 or Stage IV or M1a-b)
Total dysphagia (O'Rourke's swallowing function scoring system 5) precluding swallowing of capecitabine even when crushed
Medical or psychiatric conditions that compromise the patient's ability to give informed consent.
Patients with disease in any of the following areas on the basis of CT scan and/or endoscopic ultrasound:
Evidence of liver, lung or other distant metastases
Para-aortic/coeliac lymphadenopathy > 1cm diameter on CT, > 6mm diameter on EUS
Invasion of airways, aorta, pericardium, or lung
New York Heart Association classification Grade III or IV.
Uncontrolled angina pectoris.
Pregnancy or breast feeding.
Impaired renal function with measured creatinine clearance less than 60 ml/min.
Known malabsorption syndromes.
Patients with a known hypersensitivity to 5-FU or with a dihydropyrimidine dehydrogenase (DPD) deficiency.